Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Inclusion Criteria: * A participant will be eligible for entry into the study if all of the following criteria are met per participant self-report: * Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments. * Lives in the United States. * Adult or late adolescent, ≥ 18 years of age at the time of informed consent. * Able to read and understand the English informed consent form. * The following will be investigator-reviewed: Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD), 3rd Edition: i. Age of onset of migraines prior to 50 years of age ii. Migraine attacks, on average, lasting 4-72 hours if untreated iii. Per participant report, 4 or more migraine days per month within the last 3 months prior to the Screening Visit (a month is defined as 28 days) iv. Four to fourteen migraine days during the run-in period * Is currently managing migraines with at least 1 prescription CGRP inhibitor therapy for the preventive or acute treatment of episodic or chronic migraine during the 3 months prior to screening. * Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or later or a smartphone with an Android operating system (OS) 11 or later, and is willing to download and use the specified eDiary and Study App required by the prot…